Cargando…

Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?

The National Comprehensive Cancer Network (NCCN) has recommended Ado-trastuzumab emtansine (T-DM1) as a preferred agent for patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer and prior trastuzumab therapy. Overexpression of HER2 was reported in other canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Moghaddas, Azadeh, Borhani, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084478/
https://www.ncbi.nlm.nih.gov/pubmed/27843957
http://dx.doi.org/10.4103/2279-042X.192458